灵康药业：灵康制药产品注射用头孢唑肟钠拟中选本次集中采购

Core Viewpoint - Lingkang Pharmaceutical announced participation in the 11th national centralized drug procurement, with its product, injectable cefoperazone sodium, expected to be selected for procurement, indicating potential revenue growth for the company [1] Company Summary - Lingkang Pharmaceutical's wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., will participate in the national centralized procurement from October 27 to October 28, 2025 [1] - The projected sales for injectable cefoperazone sodium in 2024 are approximately 23.01 million yuan, accounting for 6.06% of the company's total revenue for that year [1] - For the first half of 2025, the sales of the same product are estimated at 1.82 million yuan, representing 1.06% of the company's revenue for that period [1] - The revenue composition for Lingkang Pharmaceutical in 2024 is as follows: pharmaceuticals 84.62%, pharmaceutical distribution 12.19%, other businesses 2.7%, and hospital sales and distribution 0.48% [1] - As of the report, Lingkang Pharmaceutical has a market capitalization of 4 billion yuan [1]